NCT02528617View on ClinicalTrials.gov

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Gaucher Disease Type 1Gaucher Disease Type 3
Interventions
DRUG

Velaglucerase alfa

Enzyme replacement therapy

Trial Locations (1)

75226

Baylor Research Institute, Dallas

Sponsors
All Listed Sponsors
collaborator

Texas Scottish Rite Hospital for Children

OTHER

lead

Baylor Research Institute

OTHER